Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves first generics of Lyrica


SILVER SPRING, Md., July 22, 2019 /PRNewswire/ -- On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Today's approval of the first generics for pregabalin, a widely-used medication, is another example of the FDA's longstanding commitment to advance patient access to lower cost, high-quality generic medicines," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "The FDA requires that generic drugs meet rigorous scientific and quality standards. Efficiently bringing safe and effective generics to market so patients have more options to treat their conditions is a top priority for the FDA."  

Pregabalin must be dispensed with a patient Medication Guide that contains important information about its uses and risks. Warnings include the risk of angioedema (swelling of the throat, head and neck), which may be associated with life-threatening respiratory compromise requiring emergency treatment. Hypersensitivity reactions such as hives, dyspnea (difficulty breathing) and wheezing can occur. Increased seizure frequency or other adverse reactions may occur if the drug is rapidly discontinued. Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior. Additionally, pregabalin may cause peripheral edema (swelling of hands or legs) so caution should be exercised when co-administering it with thiazolidinedione antidiabetic agents. Pregabalin may cause dizziness and drowsiness and impair ability to drive or operate machinery.

The most common side effects reported in the clinical trials for Lyrica in adults are dizziness, somnolence, dry mouth, swelling, blurred vision, weight gain and abnormal thinking (primarily difficulty with concentration/attention).

The FDA granted approvals for the generic versions of Lyrica to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy's Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.

Addressing the challenges related to developing generics and promoting more generic competition is a key part of the Drug Competition Action Plan and the agency's efforts to help advance patient access to more affordable medicines.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

 

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 05:17
EQT Infrastructure portfolio company Hector Rail Group to sell its UK subsidiary GB Railfreight, a leading rail freight operator in the United Kingdom, to Infracapital             During EQT's tenure, GB Railfreight has experienced substantial growth...

at 05:06
Archibus, a leading provider of workplace software solutions, today announced the availability of Archibus Cloud, an integrated workplace management system (IWMS) that now makes enterprise-grade SaaS more accessible. This new product aligns...

at 05:05
Market research company Technavio has released new reports on the impact of enterprise applications on the SMEs and BFSI sector. The research firm expects the enterprise resource planning (ERP) software market to register a CAGR of over 9% by 2023....

at 05:05
Keysight Technologies, Inc. , a leading technology company that helps enterprises, service providers and governments accelerate innovation to connect and secure the world, announced two new solutions - the N4891A 400GBASE Forward Error Correction...

at 05:05
September 23, 2019 New report shows how to address the challenges of implementing digital health technology ? a catalyst for achieving Universal Health Coverage (UHC)Philips Chief Medical Officer Jan Kimpen discusses the creation of enabling...

at 05:04
Aptiv and Hyundai Motor Group announced today that they will be forming an autonomous driving joint venture. This partnership brings together one of the industry's most innovative vehicle technology providers and one of the world's largest vehicle...



News published on 22 july 2019 at 10:44 and distributed by: